Skip to main content Skip to main navigation menu Skip to site footer
Review
Published: 01-20-2022

Nutrological control and treatment of melasma in the COVID-19 pandemic: a concise systematic review

Integrative Medicine Clinic, Lorena, Sao Paulo, Brazil
Melasma Skin hyperpigmentation Nutrients Dietary therapy COVID-19

Abstract

Introduction: In the skin disease scenario, hyperpigmentation (melasma) is present in about 14.5%-56% of pregnant women and 11.3%-46% of people taking oral contraceptives worldwide. The coronavirus disease 2019 (COVID-19) pandemic has brought great challenges to the treatment of melasma, as well as doubts about its worsening. Diet and nutrients for topical or oral use play an important role in the control of infectious diseases. Objective: It was to perform a concise systematic review on the occurrence, worsening, and nutrological treatment of melasma in the COVID-19 pandemic. Methods: The present study followed a systematic review model (PRISMA). After literary search criteria using MeSH Terms, a total of 98 clinical studies were compared and submitted to eligibility analysis and, after that, 70 studies were selected. The search strategy was carried out in the databases PubMed, Embase, Ovid and Cochrane Library, Web Of Science, ScienceDirect Journals (Elsevier), Scopus (Elsevier), OneFile. Results and Conclusion: Melasma is an acquired hyperpigmentation disorder, and reactive oxygen species play an important role in the regulation of melanin synthesis. In nutrological terms, lycopene is one of the most effective oxygen neutralizers among tomato-derived carotenoids. Furthermore, hydroquinone is a compound that has been used for the treatment of hyperpigmentation by tyrosinase inhibition mechanism and can be found in wheat. Thus, an adequate knowledge of the role of nutritional supplements in dermatological diseases can be a useful tool. Based on this, there is growing interest in oral medications and dietary supplements to improve melasma. Oral medications and dietary supplements evaluated include tranexamic acid, Polypodium leucotomos extract, beta-carotenoid, melatonin, and procyanidin. Also, hydrolyzed collagen is a low molecular weight protein that has been widely used and can prevent melasma. Serum zinc levels can also predict the occurrence of melasma. Finally, there is still no report on skin darkening associated with COVID-19.

Metrics

Metrics Loading ...

References

  1. Cario M. How hormones may modulate human skin pigmentation in melasma: An in vitro perspective. Exp Dermatol. 2019 Jun;28(6):709-718. doi: 10.1111/exd.13915. Epub 2019 May 15. PMID: 30883945.
  2. KrupaShankar DS, Somani VK, Kohli M, et al. A cross‐sectional, multicentric clinico‐epidemiological study of melasma in India. Dermatol Ther. 2014;4:71‐81.
  3. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J AmAcad Dermatol. 1981;4:698‐710.
  4. Passeron T. Melasma pathogenesis and influencing factors – an overview of the latest research. J Eur Acad Dermatol Venereol. 2013;27:5‐6.
  5. Handel AC, Miot LDB, Miot HA. An. Bras. Dermatol. 2014, 89, 771.
  6. Handel AC, Lima PB, Tonolli VM, Miot LD, Miot HÁ. Br. J. Dermatol. 2014, 171, 588.
  7. Esen-Salman K, Akın-Çakıcı Ö, Kardeş S, Salman A. Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic: Insights from Google Trends. Dermatol Ther. 2021 Mar;34(2):e14895. doi: 10.1111/dth.14895. Epub 2021 Feb 25. PMID: 33595849; PMCID: PMC7995005.
  8. Türsen Ü, Türsen B, Lotti T. Aesthetic dermatology procedures in coronavirus days. J Cosmet Dermatol. 2020 Aug;19(8):1822-1825. doi: 10.1111/jocd.13509. Epub 2020 Jun 18. PMID: 32460391; PMCID: PMC7283731.
  9. Garg S, Sangwan A. Dietary Protein Deficit and Deregulated Autophagy: A New Clinico-diagnostic Perspective in Pathogenesis of Early Aging, Skin, and Hair Disorders. Indian Dermatol Online J. 2019 Mar-Apr;10(2):115-124. doi: 10.4103/idoj.IDOJ_123_18. PMID: 30984584; PMCID: PMC6434747.
  10. Bavarsad N, Mapar MA, Safaezadeh M, Latifi SM. A double-blind, placebo-controlled randomized trial of skin-lightening cream containing lycopene and wheat bran extract on melasma. J Cosmet Dermatol. 2021 Jun;20(6):1795-1800. doi: 10.1111/jocd.13799. Epub 2020 Nov 5. PMID: 33151615.
  11. Sardana K, Sachdeva S. Role of nutritional supplements in selected dermatological disorders: A review. J Cosmet Dermatol. 2022 Jan;21(1):85-98. doi: 10.1111/jocd.14436. Epub 2021 Sep 26. PMID: 34564936.
  12. Zhou LL, Baibergenova A. Melasma: systematic review of the systemic treatments. Int J Dermatol. 2017 Sep;56(9):902-908. doi: 10.1111/ijd.13578. Epub 2017 Feb 27. PMID: 28239840.
  13. Aguirre-Cruz G, León-López A, Cruz-Gómez V, Jiménez-Alvarado R, Aguirre-Álvarez G. Collagen Hydrolysates for Skin Protection: Oral Administration and Topical Formulation. Antioxidants (Basel). 2020 Feb 22;9(2):181. doi: 10.3390/antiox9020181. PMID: 32098294; PMCID: PMC7070905.
  14. Rostami Mogaddam M, Safavi Ardabili N, Iranparvar Alamdari M, Maleki N, Aghabalaei Danesh M. Evaluation of the serum zinc level in adult patients with melasma: Is there a relationship with serum zinc deficiency and melasma? J Cosmet Dermatol. 2018 Jun;17(3):417-422. doi: 10.1111/jocd.12392. Epub 2017 Nov 12. PMID: 29131489.
  15. Becker S, Schiekofer C, Vogt T, Reichrath J. Melasma : Ein Update zu Klinik, Therapie und Prävention [Melasma : An update on the clinical picture, treatment, and prevention]. Hautarzt. 2017 Feb;68(2):120-126. German. doi: 10.1007/s00105-016-3927-7. PMID: 28084498.
  16. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34:e212-3.
  17. Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID-19: a French observational study. J Eur Acad Dermatol Venereol 2020, http://dx.doi.org/10.1111/jdv.16544.
  18. Diotallevi F, Campanati A, Bianchelli T, Bobyr I, Luchetti MM, Marconi B, et al. Skin involvement in SARS-CoV-2 infection: case series. J Med Virol 2020, http://dx.doi.org/10.1002/jmv.26012.
  19. Klejtman T. Skin and COVID-19. J Med Vasc. 2020 Jul;45(4):175-176. doi: 10.1016/j.jdmv.2020.06.001. PMID: 32571556; PMCID: PMC7304393.
  20. Nahhas AF, Braunberger TL, Hamzavi IH. An Update on Drug Induced Pigmentation. Am. J. Clin. Dermatol. 2019, 20, 75–96. doi: 10.1007/s40257-018-0393-2.
  21. Giménez Garcı́a RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. J. Am. Board Fam. Med. 2018, 32, 628–638. doi: 10.3122/jabfm.2019.04.180212.
  22. Li YM, Milikowski C, Selvaggi G, Abbo LM, Skiada D, Galimberti F. Polymyxin B-induced skin hyperpigmentation. Transpl. Infect. Dis. 2020, 9, e13312. doi: 10.1111/tid.13312.
  23. Zavascki AP, Manfro RC, Maciel RA, Falci DR. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy. Ann. Pharmacother. 2015, 49, 1171–1172. doi: 10.1177/1060028015595643.
  24. Gothwal S, Meena K, Sharma SD. Polymyxin B Induced Generalized Hyperpigmentation in Neonates. Indian J. Pediatr. 2016, 83, 179–180.doi: 10.1007/s12098-015-1798-z.
  25. Zheng G, Cao L, Che Z, Mao E, Chen E, He J. Polymyxin Binduced Skin Hyperpigmentation: A Rare Case Report and Literature Review. BMC Pharmacol. Toxicol. 2018, 19, 41. doi: 10.1186/s40360-018-0226-1.
  26. Mattos KP, Lloret GR, Cintra ML, Gouvea IR, Betoni TR, Mazzola PG, et al. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study. Pigment Cell Melanoma Res. 2016, 29, 388–390. doi: 10.1111/pcmr.12468.
  27. Lahiry S, Choudhury S, Mukherjee A, Bhunya PK, Bala M. Polymyxin B Induced Diffuse Cutaneous Hyperpigmentation. J. Clin. Diagn. 2017, Res. 11, FD01–FD02. doi: 10.7860/JCDR/2017/24278.9213.
  28. Lu C, Hou N. Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit? Front Pharmacol. 2020 Sep 3;11:01304. doi: 10.3389/fphar.2020.01304. PMID: 33013367; PMCID: PMC7494845.
  29. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. doi: 10.1056/NEJMoa2002032.
  30. Kaya G, Kaya A, Saurat JH. Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature. Dermatopathol. (Basel). 2020, 7, 3–16. doi: 10.3390/dermatopathology7010002.

How to Cite

Bastos, P. J. C. P. (2022). Nutrological control and treatment of melasma in the COVID-19 pandemic: a concise systematic review. International Journal of Nutrology, 15(1). https://doi.org/10.54448/ijn22106